Literature DB >> 22952222

RECIST: no longer the sharpest tool in the oncology clinical trials toolbox--reply to point.

Antonio T Fojo1, Anne Noonan.   

Abstract

Mesh：

Year:  2012        PMID： 22952222     DOI： 10.1158/0008-5472.CAN-12-1989

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  1 in total

1.  Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.

Authors:  Michael L Maitland; Matthew R Levine; Mario E Lacouture; Kristen E Wroblewski; Christine H Chung; Ilyssa O Gordon; Livia Szeto; Gail Ratko; Keyoumars Soltani; Mark F Kozloff; Philip C Hoffman; Ravi Salgia; David P Carbone; Theodore G Karrison; Everett E Vokes
Journal:  BMC Cancer       Date:  2014-01-04       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.